Fiducial markers and spacers in prostate radiotherapy: Current applications

BJU International

Volumn 113, Issue SUPPL. 2, 2014, Pages 13-20

  Ng, Michael ^a   Brown, Elizabeth ^b   Williams, Andrew ^c   Chao, Michael ^a   Lawrentschuk, Nathan ^d   Chee, Raphael ^e  

^a Radiation Oncology Victoria   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Genesis Cancer Care   (Australia)

Author keywords

Cancer; Fiducials; Prostate; Radiotherapy; Spacers

Indexed keywords

BIOMATERIAL; HYALURONIC ACID; SPACER; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; CANCER RADIOTHERAPY; DEVICE SAFETY; EQUIPMENT DESIGN; FIDUCIAL MARKER; HUMAN; HYDROGEL; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RECTUM DISEASE; REVIEW; SPACER BALLOON; COMPUTER ASSISTED RADIOTHERAPY; FIDUCIALS; FOREIGN BODY; MALE; MOVEMENT (PHYSIOLOGY); NEOPLASM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; QUALITY OF LIFE; RADIATION PROTECTION; RADIOGRAPHY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM; REPRODUCIBILITY; SPACERS;

CANCER; FIDUCIALS; PROSTATE; RADIOTHERAPY; SPACERS;

FIDUCIAL MARKERS; FOREIGN-BODY MIGRATION; HUMANS; MALE; MOVEMENT; PROSTATE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION PROTECTION; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTUM; REPRODUCIBILITY OF RESULTS;

EID: 84905390968     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12624     Document Type: Review

References (57)

1. Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-6
2. Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-105
3. Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87
4. Al-Mamgani A, van Putten WL, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8
5. Ghilezan MJ, Jaffray DA, Siewerdsen JH et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys 2005; 62: 406-17
6. Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37: 35-42
7. Schiffner DC, Gottschalk AR, Lometti M et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys2007; 67: 610-9
8. Wu J, Haycocks T, Alasti H et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 2001; 61: 127-33
9. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 236-46
10. Dinkel J, Thieke C, Plathow C et al. Respiratory-induced prostate motion: characterization and quantification in dynamic MRI. Strahlenther Onkol 2011; 187: 426-32
11. Chen J, Lee RJ, Handrahan D, Sause WT. Intensity-modulated radiotherapy using implanted fiducial markers with daily portal imaging: assessment of prostate organ motion. Int J Radiat Oncol Biol Phys 2007; 68: 912-9
12. Handsfield LL, Yue NJ, Zhou J, Chen T, Goyal S. Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: visibility and artifact analysis of gold, carbon, and polymer fiducial markers. J Appl Clin Med Phys 2012; 13: 3976
13. Habermehl D, Henkner K, Ecker S, Jäkel O, Debus J, Combs SE. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. J Radiat Res 2013; 54 (Suppl. 1): i61-8
14. Kupelian P, Willoughby T, Mahadevan A et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 1088-98
15. Quon H, Loblaw DA, Cheung PC et al. Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging.Clin Oncol (R Coll Radiol) 2012; 24: 640-5
16. Verstraete J, Van den Bergh L, de Kruijf W et al. A reliable and fast (real-time) positioning system (Navotek®) reduces the overall time per treatment session. Radiother Oncol 2011; 99: S131
17. Lei S, Piel N, Oermann EK et al. Six-dimensional correction of intra-fractional prostate motion with cyberknife stereotactic body radiation therapy. Front Oncol 2011; 48: 1-7
18. Deutschmann H, Kametriser G, Steininger P et al. First clinical release of an online, adaptive, aperture-based image-guided radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional rotations of the prostate. Int J Radiat Oncol Biol Phys 2012; 83: 1624-32
19. Kudchadker RJ, Lee AK, Yu ZH et al. Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys 2009; 74: 1283-9
20. Shinohara K, Roach M 3rd. Technique for implantation of fiducial markers in the prostate. Urology 2008; 71: 196-200
21. Linden RA, Weiner PR, Gomella LG et al. Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology 2009; 73: 881-6
22. Igdem S, Akpinar H, Alço G, Agaçayak F, Turkan S, Okkan S. Implantation of fiducial markers for image guidance in prostate radiotherapy: patient-reported toxicity. Br J Radiol 2009; 82: 941-5
23. Moman MR, van der Heide UA, Kotte AN et al. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 2010; 96: 38-42
24. Langenhuijsen JF, Donker R, McColl GM, Kiemeney LA, Witjes JA, van Lin EN. Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy: technique and complications rate. Strahlenther Onkol 2013; 189: 476-81
25. Zhu M, Bharat S, Michalski JM, Gay HA, Hou WH, Parikh PJ. Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85: 1038-44
26. Ost P, De Meerleer G, De Gersem W, Impens A, De Neve W. Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 188-94
27. Sandhu A, Sethi R, Rice R et al. Prostate bed localization with image-guided approach using on-board imaging: reporting acute toxicity and implications for radiation therapy planning following prostatectomy. Radiother Oncol 2008; 88: 20-5
28. Langenhuijsen JF, van Lin EN, Kiemeney LA et al. Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors. Int J Radiat Oncol Biol Phys 2007; 69: 671-6
29. Kupelian PA, Willoughby TR, Meeks SL et al. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys 2005; 62: 1291-6
30. Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005; 63: 800-11
31. Tiberi DA, Carrier JF, Beauchemin MC, Nguyen TV, Béliveau-Nadeau D, Taussky D. Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: e7-12
32. Fiorino C, Di Muzio N, Broggi S et al. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 2008; 71: 611-7
33. Nijkamp J, Pos FJ, Nuver TT et al. Adaptive radiotherapy for prostate cancer using kilovoltage cone-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys 2008; 70: 75-82
34. Ogino I, Uemura H, Inoue T, Kubota Y, Nomura K, Okamoto N. Reduction of prostate motion by removal of gas in rectum during radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 456-66
35. D'Amico AV, Manola J, Loffredo M et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 2001; 51: 1431-6
36. van Lin EN, Kristinsson J, Philippens ME et al. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 2007; 67: 799-811
37. Prada PJ, Fernández J, Martinez AA et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007; 69: 95-102
38. Susil RC, McNutt TR, DeWeese TL, Song D. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76: 1251-8
39. Nguyen PL, Devlin PM, Beard CJ et al. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy 2013; 12: 77-83
40. Morancy TJ, Winkfield KM, Krasiewicz CA et al. Use of a blood-patch technique to reduce rectal dose during cesium-131 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72: S331-2
41. Noyes WR, Hosford CC, Schultz SE. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82: 1918-22
42. Pinkawa M, Piroth MD, Holy R et al. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiother Oncol 2013; 106: 220-4
43. Pinkawa M, Corral NE, Caffaro M et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011; 100: 436-41
44. Hatiboglu G, Pinkawa M, Vallée JP, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 2012; 110: E647-52
45. Ben-Yosef R, Paz A, Levy Y et al. A novel device for protecting rectum during prostate cancer irradiation: in vivo data on a large mammal model. J Urol 2009; 181: 1401-6
46. Gez E, Cytron S, Yosef RB et al. Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol 2013; 8: 96 [Epub 23 April 2013]
47. Eckert F, Alloussi S, Paulsen F et al. Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer 2013; 13: 27
48. Prada PJ, Gonzalez H, Menéndez C et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009; 8: 210-7
49. Wilder RB, Barme GA, Gilbert RF et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77: 824-30
50. Wilder RB, Barme GA, Gilbert RF et al. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 2011; 10: 44-50
51. Weber DC, Zilli T, Vallee JP, Rouzaud M, Miralbell R, Cozzi L. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study. Int J Radiat Oncol Biol Phys 2012; 84: e311-8
52. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl. 3): S123-9
53. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl. 3): S116-22
54. Pinkawa M, Piroth MD, Holy R et al. Quality of life after intensitymodulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis. Strahlenther Onkol 2012; 188: 917-25
55. Song DY, Herfarth KK, Uhl M et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 2013; 87: 81-7
56. Melchert C, Gez E, Bohlen G et al. Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol 2013; 106: 210-4
57. Vargas C, Martinez A, Kestin LL et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 1297-308